Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates improved liver and lung graft function through ferroptosis inhibition, highlighting ex vivo perfusion as a therapeutic window for organ repair.
In a recent study published in Cell, Veeckmans et al. show that small molecule ferroptosis inhibitors can improve liver and lung graft function. 1 These results demonstrate that ferroptosis is an emerging targetable driver of ischemia–reperfusion injury (IRI) and highlight the critical role of ex vivo organ perfusion as a therapeutic window for graft repair before transplantation.
No takes yet. Share an insight, caveat, or question.
Xing et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: